1887

Abstract

Survival of mice infected with an intravenous injection of was observed in a short-term (21-day) survival study. Concentration of in the kidneys, liver, and spleen was determined at various times. The effects of treatment with the commercial formulation of amphotericin B (fAMB), liposomal amphotericin B (LAMB), and liposomal amphotericin B bearing external antibody specific for (LAMB-Ab) were compared. In single intravenous treatment dosages of 0.6 mg of amphotericin B/kg, the liposomal forms of the drug (LAMB and LAMB-Ab) enhanced the percentage survival and mean survival time of mice in comparison with those treated with the unencapsulated antifungal compound, fAMB (p <0.03 and p<0.001, respectively). LAMB-Ab, at this dosage, produced an increase in the survival (p<0.007) of mice over that produced by LAMB. LAMB-Ab treatment caused a greater than 3-fold increase over fAMB. The percentage of LAMB-Ab-treated mice which survived for 21 days was almost double that of the LAMB-treated mice. The increase in survival following this treatment did not, however, lead to the eradication of in all mice which survived to the end of the experiment.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-30-3-193
1989-11-01
2019-10-14
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-30-3-193
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error